Advertisement
Home »

Hepatotoxicity of AKR1C3 Inhibitor BAY1128688: Findings from an Early Terminated Phase IIa Trial for the Treatment of Endometriosis.

Jul 10, 2023

ABOUT THE EXPERTS

  • Jan Hilpert

    Pharmaceuticals, Bayer AG, Berlin, Germany. jan.hilpert@bayer.com.

    Esther Groettrup-Wolfers

    Pharmaceuticals, Bayer AG, Berlin, Germany.

    Hristiyan Kosturski

    Svelte® scientific GmbH, Berlin, Germany.

    Laura Bennett

    Fios Genomics Ltd, Edinburgh, UK.

    Catriona L K Barnes

    Fios Genomics Ltd, Edinburgh, UK.

    Kerstin Gude

    Pharmaceuticals, Bayer AG, Berlin, Germany.

    Isabella Gashaw

    Pharmaceuticals, Bayer AG, Berlin, Germany.

    Stefanie Reif

    Pharmaceuticals, Bayer AG, Berlin, Germany.

    Thomas Steger-Hartmann

    Pharmaceuticals, Bayer AG, Berlin, Germany.

    Christian Scheerans

    Pharmaceuticals, Bayer AG, Berlin, Germany.

    Alexander Solms

    Pharmaceuticals, Bayer AG, Berlin, Germany.

    Antje Rottmann

    Pharmaceuticals, Bayer AG, Berlin, Germany.

    Guangping Mao

    Pharmaceuticals, Bayer AG, Berlin, Germany.

    Charles Chapron

    Department of Gynecology, Obstetrics II, and Reproductive Medicine, Faculté de Santé, Faculté de Médecine Paris Centre, Université de Paris, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement